<DOC>
	<DOCNO>NCT03106662</DOCNO>
	<brief_summary>Mesenchymal stem cell ( MSCs ) use treatment prevention graft-versus host disease ( GVHD ) . In study investigator aim present efficacy mesenchymal stem cell graft versus host disease prophylaxis effect engraftment haploidentical recipient . Forty patient age old 18 indication haploidentical hematopoietic stem cell transplantation include study . MSCs isolate donor bone marrow infuse patient condition regimen day +6 . If haploidentical transplantation result improve MSCs treatment would possible ameliorate problem HLA-matched donor paucity Turkey prefer haploidentical donor .</brief_summary>
	<brief_title>Mesenchymal Stem Cell Infusion Haploidentical Hematopoietic Stem Cell Transplantation Patients With Hematological Malignancies</brief_title>
	<detailed_description>Mesenchymal stem cell ( MSCs ) utilize treatment prevention graft-versus-host disease ( GVHD ) allogeneic hematopoietic stem cell transplantation ( alloSCT ) . However , study MSC use alloSCT haploidentical donor ( haploSCT ) limit . In study , investigator aim 1 ) evaluate MSCs ' efficacy GVHD prophylaxis effect engraftment haploidentical graft , 2 ) improve success rate haploSCT decrease GVHD incidence graft failure rate . With high haploSCT success rate , haploidentical donor would important alternative graft source patient without HLA-matched donor . Forty patient present Ankara University , School Medicine , Division Hematology hematological malignancy indication haploSCT include study inform consent obtain . MSCs procure isolated donor bone marrow . MSCs isolate , culture , store good manufacturing practice ( GMP ) laboratory Ankara University Stem Cell Institute . Donor bone marrow harvest , four six week prior transplantation , MSC isolation culture . Patients receive either ablative non-ablative induction regimen base age , diagnosis , disease status time transplantation . Donor bone marrow harvest second time day transplantation procure bone marrow graft infused patient day . GVHD prophylaxis include post-transplantation cyclophosphamide ( Cy ) day +3 +4 ( 50 mg/kg/day ) , tacrolimus , mycophenolate mofetil . Stored MSCs infuse patient day +6 . The endpoint include graft failure rate , GVHD incidence , transplant-related mortality , disease-free survival , overall survival . The investigator aim evaluate utility MSCs improve haploSCT result enhance reliability success haploSCT . Successful transplant haploidentical donor would ameliorate problem match donor paucity country limit number hematopoietic stem cell donor , Turkey , would establish haploidentical donor alternative donor source patient without matched donor Turkey . As haploidentical donor may parent child , rapid easy access donor would decrease wait time alloSCT . Moreover , national current account deficit may reduce use graft obtain haploidentical donor reside Turkey instead graft foreign stem cell/umbilical cord bank . In project , investigator seek develop clinical therapy application concordant ambition `` renewal repair human cell , tissue , organ cellular therapy cellular product '' include The Scientific Technological Research Council Turkey 1003 Call Projects .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Diagnosed haematological malignancy Indication haploidentical hematopoietic stem cell transplantation No restriction transplantation Any restriction transplantation No indication haploidentical hematopoietic stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>haploidentical hematopoietic stem cell transplantation</keyword>
	<keyword>graft-versus-host disease</keyword>
	<keyword>engraftment</keyword>
</DOC>